Sanofi, GSK tie up for COVID-19 vaccine work with eyes on possible 2021 rollout

Sanofi and GlaxoSmithKline, two of the world’s biggest vaccine players, may be competitors, but the COVID-19 pandemic has now made them partners.

In an unprecedented tie-up unveiled Tuesday, the companies are joining forces to work on a potential COVID-19 vaccine. They aim to start human testing in the second half of this year, and if all goes well, to file for potential approvals by the second half of 2021.